3 Einträge von 3 mit transplant clinical
www.cslbehring.ch
Datum der Indexierung 13.03.2021 14:18:31
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase research | with market | transplant clinical | anti global | cidp privigen | products study | breakthrough hizentra | medicines development | specialty haemophilia | patients immunoglobulins |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summary Andrew Cuthbertson • Q&A 4 Commitment to Research and Development 5 Research and Development Investment (US$ Mill Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summa
Text Inhalt Text aus URL
Log Metriken 469967
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase research | with market | transplant clinical | anti global | cidp privigen | products study | breakthrough hizentra | medicines development | specialty haemophilia | patients immunoglobulins |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summary Andrew Cuthbertson • Q&A 4 Commitment to Research and Development 5 Research and Development Investment (US$ Mill Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summa
Text Inhalt Text aus URL
Log Metriken 469967
www.cslbehring.ch
Datum der Indexierung 05.05.2021 04:36:59
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=494FDD9185B1042615BEEBFB38FFDCB1D72C821B
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summary Andrew Cuthbertson • Q&A 4 Commitment to Research and Development 5 Research and Development Investment (US$ Mill Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summa
Text Inhalt Text aus URL
Log Metriken 446193
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=fr-fr&hash=494FDD9185B1042615BEEBFB38FFDCB1D72C821B
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summary Andrew Cuthbertson • Q&A 4 Commitment to Research and Development 5 Research and Development Investment (US$ Mill Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summa
Text Inhalt Text aus URL
Log Metriken 446193
www.cslbehring.ch
Datum der Indexierung 05.05.2021 07:42:21
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summary Andrew Cuthbertson • Q&A 4 Commitment to Research and Development 5 Research and Development Investment (US$ Mill Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summa
Text Inhalt Text aus URL
Log Metriken 469967
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summary Andrew Cuthbertson • Q&A 4 Commitment to Research and Development 5 Research and Development Investment (US$ Mill Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Summa
Text Inhalt Text aus URL
Log Metriken 469967